ETF Holdings Breakdown of MGNX

Stock NameMacroGenics Inc
TickerMGNX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5560991094
LEI5493001KJQUA83L8MH79

News associated with MGNX

Price T Rowe Associates Inc. MD Lowers Stake in MacroGenics, Inc. (NASDAQ:MGNX)
Price T Rowe Associates Inc. MD decreased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 61.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 485,987 shares of the biopharmaceutical company’s stock after selling 768,249 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in MacroGenics were worth $1,581,000 […] - 2025-05-09 09:25:03
Marshall Wace LLP Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)
Marshall Wace LLP grew its holdings in MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 393,766 shares of the biopharmaceutical company’s stock after acquiring an additional 12,250 shares during the period. Marshall Wace […] - 2025-04-30 08:41:02
XTX Topco Ltd Acquires 55,564 Shares of MacroGenics, Inc. (NASDAQ:MGNX)
XTX Topco Ltd grew its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 497.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,742 shares of the biopharmaceutical company’s stock after acquiring an additional 55,564 shares during the […] - 2025-04-28 09:20:59
JPMorgan Chase & Co. Increases Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)
JPMorgan Chase & Co. increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 68.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 546,807 shares of the biopharmaceutical company’s stock after buying an additional 221,905 shares during the period. JPMorgan Chase & Co.’s holdings in MacroGenics were worth $1,777,000 as […] - 2025-04-25 07:18:49
HC Wainwright Lowers MacroGenics (NASDAQ:MGNX) Price Target to $2.00
MacroGenics (NASDAQ:MGNX – Free Report) had its price objective cut by HC Wainwright from $4.00 to $2.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Separately, StockNews.com downgraded MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, […] - 2025-03-26 06:52:44
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from Analysts
MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has been given an average recommendation of “Hold” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. […] - 2025-03-26 05:53:00

MGNX institutional holdings

The following institutional investment holdings of MGNX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 73,266USD 112,830
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 28,773USD 44,310
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 28,773USD 44,310 3.2%
Total =130,812 USD 201,450
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.